Disulfide bond disruption by a β3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active αIIbβ3

 

 Buy Article Permissions and Reprints

Summary

αIIbβ3 integrin mediates platelet aggregation following its activation. Its absence or dysfunction causes Glanzmann thrombasthenia (GT), an inherited bleeding disorder that is rare worldwide but relatively frequent in several populations with high rates of consanguinity, including Arabs in Israel and Jordan. Cysteine residues in the β3 epidermal growth factor (EGF) domains are involved in αIIbβ3 formation and activation. In this study we present a novel Cys549Arg mutation in β3 identified in six Jordanian families, which in the homozygous state is manifested by severe GT. The mutation is located in EGF-3 of β3 predicting disruption of a conserved disulfide bond between Cys549 and Cys558. Haplotype analysis disclosed a common founder whose age estimate was 120–150 years. Flow cytometry revealed 1–14% of normal αIIbβ3 expression at the patients' platelet surface. The Cys549Arg or artificial Cys549Ser mutations were introduced into a β3 expression vector. Co-transfection of baby hamster kidney cells with normal or mutant β3 along with normal αIIb demonstrated reduced surface expression of αIIbβ3 by both mutants. The mutants were constitutively active as demonstrated by 20-fold increased binding of the ligand-mimetic antibody PAC-1. Immunoblotting and immunoprecipitation experiments showed reduced β3 and αIIbβ3 expression and a higher than normal ratio of pro-αIIb to mature αIIb. Immunofluorescence experiments showed that β3 and αIIbβ3 were mostly retained in the endoplasmic reticulum. In conclusion, the novel ancestral mutation found in a cluster of Jordanian GT patients disrupts a conserved Cys549-Cys558 bond which results in reduced production of constitutively active αIIbβ3.

^* These authors contributed equally to this work.

• References

• 1 Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
  CrossrefPubMedGoogle Scholar
• 2 Xiao T, Takagi J, Coller BS. et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
  CrossrefPubMedGoogle Scholar
• 3 Seligsohn U, Rososhansky S. A Glanzmann’s thrombasthenia cluster among Iraqi Jews in Israel. Thromb Haemost 1984; 52: 230-231.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Schlegel N, Gayet O, Morel-Kopp MC. et al. The molecular genetic basis of Glanzmann’s thrombasthenia in a Gypsy population in France: identification of a new mutation on the alpha IIb gene. Blood 1995; 86: 977-982.
  PubMedGoogle Scholar
• 5 Peretz H, Rosenberg N, Landau M. et al. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structurefunction correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat 2006; 27: 359-369.
  CrossrefPubMedGoogle Scholar
• 6 Awidi AS. Rare inherited bleeding disorders secondary to coagulation factors in Jordan: A nine-year study. Acta Haematol 1992; 88: 11-13.
  CrossrefPubMedGoogle Scholar
• 7 Newman PJ, Seligsohn U, Lyman S. et al. The molecular basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA 1991; 88: 3160-3164.
  CrossrefPubMedGoogle Scholar
• 8 Rosenberg N, Hauschner H, Peretz H. et al. A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost 2005; 3: 2764-2772.
  CrossrefPubMedGoogle Scholar
• 9 Xiong JP, Stehle T, Diefenbach B. et al. Crystal structure of the extracellular segment of integrin alphaVbeta3. Science 2001; 294: 339-345.
  CrossrefPubMedGoogle Scholar
• 10 Grimaldi CM, Chen F, Scudder LE. et al. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann’s thrombasthenia. Blood 1996; 88: 1666-1675.
  PubMedGoogle Scholar
• 11 Milet-Marsal S, Breillat C, Peyruchaud O. et al. Two different beta3 cysteine substitutions alter alphaIIb beta3 maturation and result in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 104-110.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Nair S, Li J, Mitchell WB. et al. Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3. Thromb Haemost 2002; 88: 503-509.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Ruan J, Schmugge M, Clemetson KJ. et al. Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann’s thrombasthenia. Br J Haematol 1999; 105: 523-531.
  CrossrefPubMedGoogle Scholar
• 14 Ambo H, Kamata T, Handa M. et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun 1998; 251: 763-768.
  CrossrefPubMedGoogle Scholar
• 15 Ruiz C, Liu CY, Sun QH. et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-2441.
  CrossrefPubMedGoogle Scholar
• 16 Chen P, Melchior C, Brons NH. et al. Probing conformational changes in the I-like domain and the cysteine- rich repeat of human beta 3 integrins following disulfide bond disruption by cysteine mutations: identification of cysteine 598 involved in alphaIIbbeta3 activation. J Biol Chem 2001; 276: 38628-38635.
  CrossrefPubMedGoogle Scholar
• 17 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215-1219.
  CrossrefPubMedGoogle Scholar
• 18 Yatuv R, Rosenberg N, Dardik R. et al. Glanzmann thrombasthenia in two Iraqi-Jewish siblings is caused by a novel splice junction mutation in the glycoprotein IIb. Blood Coagul Fibrinolysis 1998; 9: 285-288.
  CrossrefPubMedGoogle Scholar
• 19 Orita M, Suzuki Y, Sekiya T. et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
  CrossrefPubMedGoogle Scholar
• 20 French DL, Coller BS, Usher S. et al. Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. Br J Haematol 1998; 102: 582-587.
  CrossrefPubMedGoogle Scholar
• 21 Rosenberg N, Yatuv R, Sobolev V. et al. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation but abolish its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 2003; 101: 4808-4815.
  CrossrefPubMedGoogle Scholar
• 22 Bateman A, Coin L, Durbin R. et al. The Pfam protein families database. Nucleic Acids Res 2004; 32: D138-D141.
  CrossrefPubMedGoogle Scholar
• 23 Eddy SR. Hidden Markov models. Curr Opin Struct Biol 1996; 6: 361-365.
  CrossrefPubMedGoogle Scholar
• 24 Bairoch A, Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999. Nucleic Acids Res 1999; 27: 49-54.
  CrossrefPubMedGoogle Scholar
• 25 Herrmann FH, Meyer M, Gogstad GO. et al. Glycoprotein IIb-IIIa complex in platelets of patients and heterozygotes of Glanzmann’s thrombasthenia. Thromb Res 1983; 32: 615-622.
  CrossrefPubMedGoogle Scholar
• 26 Coller BS, Seligsohn U, Zivelin A. et al. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol 1986; 62: 723-735.
  CrossrefPubMedGoogle Scholar
• 27 Risch N, de Leon D, Ozelius L. et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 1995; 9: 152-159.
  CrossrefPubMedGoogle Scholar
• 28 Takagi J, Beglova N, Yalamanchili P. et al. Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits. Proc Natl Acad Sci USA 2001; 98: 11175-11180.
  CrossrefPubMedGoogle Scholar
• 29 Beglova N, Blacklow SC, Takagi J. et al. Cysteinerich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol 2002; 9: 282-287.
  CrossrefPubMedGoogle Scholar
• 30 Gonzalez-Manchon C, Butta N, Larrucea S. et al. A variant thrombasthenic phenotype associated with compound heterozygosity of integrin beta3-subunit: (Met124Val)beta3 alters the subunit dimerization rendering a decreased number of constitutive active alphaIIbbeta3 receptors. Thromb Haemost 2004; 92: 1377-1386.
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Yan B, Smith JW. A redox site involved in integrin activation. J Biol Chem 2000; 275: 39964-39972.
  CrossrefPubMedGoogle Scholar
• 32 Lahav J, Jurk K, Hess O. et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100: 2472-2478.
  CrossrefPubMedGoogle Scholar
• 33 Lahav J, Gofer-Dadosh N, Luboshitz J. et al. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett 2000; 475: 89-92.
  CrossrefPubMedGoogle Scholar
• 34 Kamata T, Ambo H, Puzon-McLaughlin W. et al. Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit. Biochem J 2004; 378: 1079-1082.
  CrossrefPubMedGoogle Scholar